Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAR 442085

Next Previous
Drug Profile

SAR 442085

Alternative Names: SAR442085

Latest Information Update: 06 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Class Antineoplastics
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Phagocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple myeloma

Most Recent Events

  • 19 Sep 2023 Sanofi terminates phase I trial in Multiple myeloma (Second-line therapy or greater) in Czech Republic, France, Greece, Taiwan, Spain and US (IV) due to sponsor decision for reasons unrelated to safety, in reviewing Sponsor's evolving portfolio and strategic prioritisation (NCT04000282) (EudraCT2019-001018-40)
  • 31 Dec 2021 Discontinued - Phase-I for Multiple myeloma (Second-line therapy or greater) in Czech Republic, Greece, Spain, France (IV)
  • 31 Dec 2021 Discontinued - Phase-I for Multiple myeloma (Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top